Leidos Holdings, Inc LDOS reported better-than-expected second-quarter fiscal 2024 earnings on Tuesday.
The company posted revenue growth of 8% year-over-year to $4.13 billion, beating the analyst consensus estimate of $4.06 billion, driven by demand across all customer segments, especially for managed health services. The defense, aviation, information technology, and biomedical research company's adjusted EPS was $2.63, up 46% year over year, beating the analyst consensus estimate of $2.27.
CEO Thomas Bell commented, "Our collaborative innovation strategy and capabilities-based organization position us well to deliver on our commitments for the remainder of 2024 and beyond."
Leidos expects fiscal 2024 revenue of $16.1 billion-$16.4 billion (prior $16.0 billion – $16.4 billion). The analyst consensus stands at $16.25 billion. The company expects its fiscal 2024 adjusted EPS of $8.60 – $9.00 (prior $8.40 – $8.80) versus the $8.82 consensus.
Leidos shares fell 2% to trade at $143.04 on Wednesday.
These analysts made changes to their price targets on Leidos following earnings announcement.
- RBC Capital analyst Ken Herbert maintained Leidos with a Sector Perform rating, while raising the price target from $140 to $145.
- JP Morgan analyst Seth Seifman maintained the stock with an Overweight rating and increased the price target from $165 to $175.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.